Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
暂无分享,去创建一个
F. D. De Braud | A. Anichini | M. Milione | A. Occhini | A. Maurichi | R. Mortarini | F. Corti | G. Bertino | M. Torchio | S. Pusceddu | N. Prinzi | J. Coppa | M. Di Bartolomeo | L. Cattaneo | M. Ungari
[1] Parantu K. Shah,et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial , 2020, Journal for immunotherapy of cancer.
[2] T. Steiniche,et al. Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma , 2020, Cancers.
[3] G. Gao,et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy , 2020, Proceedings of the National Academy of Sciences.
[4] C. Drake,et al. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 , 2019, Journal of Immunotherapy for Cancer.
[5] M. Tetzlaff,et al. Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma , 2019, Modern Pathology.
[6] A. Sykes,et al. Electrochemotherapy and Ablative Therapies in Non-melanoma Skin Cancer. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).
[7] Howard Y. Chang,et al. Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.
[8] V. Mazzaferro,et al. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms , 2019, The journal of pathology. Clinical research.
[9] G. Linette,et al. A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.
[10] J. Taube,et al. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Carola Berking,et al. Melanoma , 2018, The Lancet.
[12] J. Grob,et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial , 2018, JAMA oncology.
[13] A. Stang,et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics , 2017, Journal of the American Academy of Dermatology.
[14] J. Becker,et al. Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC , 2018, Cancer Immunology, Immunotherapy.
[15] C. Garbe,et al. Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy , 2017, Reviews in Endocrine and Metabolic Disorders.
[16] Lu Shi,et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.
[17] J. Schlom,et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.
[18] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[19] D. Schadendorf,et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. , 2017, European journal of cancer.
[20] G. Linette,et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[21] N. Pimpinelli,et al. CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy , 2016, Clinical & Experimental Metastasis.
[22] A. Sober,et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System , 2016, Annals of Surgical Oncology.
[23] George F. Murphy,et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.
[24] D. Miklavčič,et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer , 2015, Cancer Immunology, Immunotherapy.
[25] M. Benazzo,et al. Electrochemotherapy as a new therapeutic strategy in advanced Merkel cell carcinoma of head and neck region , 2013, Radiology and oncology.
[26] S. Calvieri,et al. Remission of extensive merkel cell carcinoma after electrochemotherapy. , 2009, Archives of dermatology.
[27] M. Ming,et al. Merkel cell carcinoma , 2004, Current treatment options in oncology.